Alcon and RxSight Team Up to Develop Adjustable Premium IOLs
Alcon and RxSight have entered a non-exclusive licensing agreement to jointly develop light-adjustable presbyopia-correcting intraocular lenses (PCIOLs), the companies announced this week, pairing Alcon's premium optical designs with RxSight's post-operative adjustment platform.
Announced Monday from Geneva, the collaboration will combine RxSight's Light Adjustable Lens (LAL) technology, currently the only commercially available IOL that can be fine-tuned after cataract surgery, with Alcon's PCIOL optical designs. The goal is a co-developed lens that lets surgeons refine a patient's visual outcome once healing is complete, rather than locking in the result at the time of implantation.
For cataract surgeons, the appeal of adjustable technology is straightforward: presbyopia-correcting lenses promise spectacle independence, but outcomes can vary due to factors like corneal healing and effective lens position that aren't fully known until after surgery. A lens that can be tuned post-operatively offers a second chance to get the result right, an especially attractive proposition for the growing premium IOL segment.
Alcon chief executive David J. Endicott said the tie-up builds on lenses that have already helped millions of patients reduce or eliminate their reliance on glasses after cataract surgery, and that pairing them with RxSight's adjustability would give surgeons more confidence in refining post-surgical outcomes. RxSight president and chief executive Ron Kurtz said the deal reflects the company's belief in the importance of adjustability and should help extend the technology to a broader patient base.
Deal structure
Under the agreement:
- RxSight will receive a US$60 million (approximately A$86.5 million) upfront payment to begin development
- RxSight is eligible for up to a further US$140 million (approximately A$202 million) tied to development and regulatory milestones
- Alcon will lead global commercialisation
- RxSight will handle development and manufacturing, and will earn royalties on net sales
The arrangement is non-exclusive, meaning both companies retain flexibility to pursue other partnerships or independent development in the adjustable-lens space.
What it means for the market
The deal signals growing confidence among major eye care players that adjustable optics, rather than fixed-design premium IOLs alone, represent the next phase of competition in presbyopia correction. RxSight's LAL system, which uses its Light Delivery Device to reshape the lens non-invasively after implantation, has so far been the sole adjustable option on the market. A partnership with Alcon, one of the largest suppliers of surgical and vision care products globally, could significantly widen its footprint if the co-developed lenses reach commercialisation.
No timeline for regulatory submission or launch was disclosed. As with any early-stage collaboration, development and approval milestones, and the eventual product's clinical performance, will determine how quickly, if at all, adjustable PCIOLs move from announcement to the operating theatre.
